|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang L: Incidence and mortality of gastric
cancer in China. World J Gastroenterol. 12:17–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang J, Dang P, Raut CP, Pandalai PK,
Maduekwe UN, Rattner DW, Lauwers GY and Yoon SS: Comparison of a
lymph node ratio-based staging system with the 7th AJCC system for
gastric cancer: Analysis of 18,043 patients from the SEER database.
Ann Surg. 255:478–485. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nashimoto A: Current status of treatment
strategy for elderly patients with gastric cancer. Int J Clin
Oncol. 18:969–970. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nadauld LD, Garcia S, Natsoulis G, Bell
JM, Miotke L, Hopmans ES, Xu H, Pai RK, Palm C, Regan JF, et al:
Metastatic tumor evolution and organoid modeling implicate TGFBR2
as a cancer driver in diffuse gastric cancer. Genome Biol.
15:4282014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Keighley MR: Gastrointestinal cancers in
Europe. Aliment Pharmacol Ther. 18 Suppl 3:S7–S30. 2003. View Article : Google Scholar
|
|
7
|
Fang N, Zhang HQ, He B, Xie M, Lu S, Wan
YY and Wang NR: Clinicopathological characteristics and prognosis
of gastric cancer with malignant ascites. Tumour Biol.
35:3261–3268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wierstra I and Alves J: FOXM1, a typical
proliferation-associated transcription factor. Biol Chem.
388:1257–1274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang IC, Chen YJ, Hughes D, Petrovic V,
Major ML, Park HJ, Tan Y, Ackerson T and Costa RH: Forkhead box M1
regulates the transcriptional network of genes essential for
mitotic progression and genes encoding the SCF (Skp2-Cks1)
ubiquitin ligase. Mol Cell Biol. 25:10875–10894. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Costa RH: FoxM1 dances with mitosis. Nat
Cell Biol. 7:108–110. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kopanja D, Pandey A, Kiefer M, Wang Z,
Chandan N, Carr JR, Franks R, Yu DY, Guzman G, Maker A and
Raychaudhuri P: Essential roles of FoxM1 in Ras-induced liver
cancer progression and in cancer cells with stem cell features. J
Hepatol. 63:429–436. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Zhang J, Cui X, Yang Y, Li M, Qu
J, Li J and Wang J: FoxM1: A novel tumor biomarker of lung cancer.
Int J Clin Exp Med. 8:3136–3140. 2015.PubMed/NCBI
|
|
14
|
Bergamaschi A, Madak-Erdogan Z, Kim YJ,
Choi YL, Lu H and Katzenellenbogen BS: The forkhead transcription
factor FOXM1 promotes endocrine resistance and invasiveness in
estrogen receptor-positive breast cancer by expansion of stem-like
cancer cells. Breast Cancer Res. 16:4362014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wan X, Yeung C, Kim SY, Dolan JG, Ngo VN,
Burkett S, Khan J, Staudt LM and Helman LJ: Identification of
FoxM1/Bub1b signaling pathway as a required component for growth
and survival of rhabdomyosarcoma. Cancer Res. 72:5889–5899. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ferraris GM and Sidenius N: Urokinase
plasminogen activator receptor: A functional integrator of
extracellular proteolysis, cell adhesion, and signal transduction.
Semin Thromb Hemost. 39:347–355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sidenius N and Blasi F: The urokinase
plasminogen activator system in cancer: Recent advances and
implication for prognosis and therapy. Cancer Metastasis Rev.
22:205–222. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Duffy MJ: The urokinase plasminogen
activator system: Role in malignancy. Curr Pharm Des. 10:39–49.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rabbani SA and Mazar AP: The role of the
plasminogen activation system in angiogenesis and metastasis. Surg
Oncol Clin N Am. 10(393–415): x2001.
|
|
20
|
Duffy MJ, Maguire TM, McDermott EW and
O'Higgins N: Urokinase plasminogen activator: A prognostic marker
in multiple types of cancer. J Surg Oncol. 71:130–135. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Choong PF and Nadesapillai AP: Urokinase
plasminogen activator system: A multifunctional role in tumor
progression and metastasis. Clin Orthop Relat Res. 415
Suppl:S46–S58. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Plebani M, Herszènyi L, Carraro P, De
Paoli M, Roveroni G, Cardin R, Tulassay Z, Naccarato R and Farinati
F: Urokinase-type plasminogen activator receptor in gastric cancer:
Tissue expression and prognostic role. Clin Exp Metastasis.
15:418–425. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu B, El Hajj N, Sittler S, Lammert N,
Barnes R and Meloni-Ehrig A: Gastric cancer: Classification,
histology and application of molecular pathology. J Gastrointest
Oncol. 3:251–261. 2012.PubMed/NCBI
|
|
24
|
Halasi M and Gartel AL: FOX(M1) news-it is
cancer. Mol Cancer Ther. 12:245–254. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeng J, Wang L, Li Q, Li W, Björkholm M,
Jia J and Xu D: FoxM1 is up-regulated in gastric cancer and its
inhibition leads to cellular senescence, partially dependent on p27
kip1. J Pathol. 218:419–427. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Okada K, Fujiwara Y, Takahashi T, Nakamura
Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori
M and Doki Y: Overexpression of forkhead box M1 transcription
factor (FOXM1) is a potential prognostic marker and enhances
chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol.
20:1035–1043. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li X, Qi W, Yao R, Tang D and Liang J:
Overexpressed transcription factor FOXM1 is a potential diagnostic
and adverse prognostic factor in postoperational gastric cancer
patients. Clin Transl Oncol. 16:307–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hui MK, Chan KW, Luk JM, Lee NP, Chung Y,
Cheung LC, Srivastava G, Tsao SW, Tang JC and Law S: Cytoplasmic
Forkhead box M1 (FoxM1) in esophageal squamous cell carcinoma
significantly correlates with pathological disease stage. World J
Surg. 36:90–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen CH, Chien CY, Huang CC, Hwang CF,
Chuang HC, Fang FM, Huang HY, Chen CM, Liu HL and Huang CY:
Expression of FLJ10540 is correlated with aggressiveness of oral
cavity squamous cell carcinoma by stimulating cell migration and
invasion through increased FOXM1 and MMP-2 activity. Oncogene.
28:2723–2737. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Z, Banerjee S, Kong D, Li Y and
Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor
leads to the inhibition of invasion and angiogenesis of pancreatic
cancer cells. Cancer Res. 67:8293–8300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D,
Huang S, Tan D and Xie K: Critical role and regulation of
transcription factor FoxM1 in human gastric cancer angiogenesis and
progression. Cancer Res. 69:3501–3509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Petersen LC, Lund LR, Nielsen LS, Danø K
and Skriver L: One-chain urokinase-type plasminogen activator from
human sarcoma cells is a proenzyme with little or no intrinsic
activity. J Biol Chem. 263:11189–11195. 1988.PubMed/NCBI
|
|
33
|
Bekes EM, Deryugina EI, Kupriyanova TA,
Zajac E, Botkjaer KA, Andreasen PA and Quigley JP: Activation of
pro-uPA is critical for initial escape from the primary tumor and
hematogenous dissemination of human carcinoma cells. Neoplasia.
13:806–821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tang L and Han X: The urokinase
plasminogen activator system in breast cancer invasion and
metastasis. Biomed Pharmacother. 67:179–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heiss MM, Simon EH, Beyer BC, Gruetzner
KU, Tarabichi A, Babic R, Schildberg FW and Allgayer H: Minimal
residual disease in gastric cancer: Evidence of an independent
prognostic relevance of urokinase receptor expression by
disseminated tumor cells in the bone marrow. J Clin Oncol.
20:2005–2016. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Herceg Horvatic G, Herceg D, Kralik M,
Kulic A, Bence-Zigman Z, Tomic-Brzac H, Bracic I, Kusacic-Kuna S
and Prgomet D: Urokinase plasminogen activator and its inhibitor
type-1 as prognostic factors in differentiated thyroid carcinoma
patients. Otolaryngol Head Neck Surg. 149:533–540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu HY, Shen XH, Ni RS, Qian XY and Gao X:
Expression of E-cadherin and uPA and their prognostic value in
carcinoma of human larynx. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke
Za Zhi. 44:1024–1028. 2009.(In Chinese). PubMed/NCBI
|
|
38
|
Chen H, Zou Y, Yang H, Wang J and Pan H:
Downregulation of FoxM1 inhibits proliferation, invasion and
angiogenesis of HeLa cells in vitro and in vivo. Int J Oncol.
45:2355–2364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ahmad A, Wang Z, Kong D, Ali S, Li Y,
Banerjee S, Ali R and Sarkar FH: FoxM1 down-regulation leads to
inhibition of proliferation, migration and invasion of breast
cancer cells through the modulation of extra-cellular matrix
degrading factors. Breast Cancer Res Treat. 122:337–346. 2010.
View Article : Google Scholar : PubMed/NCBI
|
